Becton, Dickinson and Company (NYSE:BDX) is included among the 11 Best Rising Dividend Stocks to Buy Right Now.
On May 11, Barclays raised its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $204 from $202. It reiterated an Overweight rating on the shares following the company’s fiscal Q2 results. The firm said Becton delivered solid operational growth and exceeded consensus expectations. The analyst also noted that the company appears well-positioned in the current macro environment.
During the fiscal Q2 2026 earnings call, President, CEO, and Chairman Thomas Polen said revenue increased 2.6% to $4.7 billion. He pointed to double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. At the same time, Polen said results were partly offset by continued pressure in Alaris, vaccines, and China, which together represented less than 10% of total revenue.
Polen also said the company gained around 50 basis points of market share during the quarter and roughly 150 basis points year-to-date in the Alaris business. In the BioPharma Systems segment, he noted that BD secured several large long-term customer agreements, including two next-generation GLP-1 programs. He added that biologics are now expected to account for about 55% of segment revenue.
Discussing regulatory matters, Polen said the company voluntarily placed its ChloraPrep and PurPrep products on ship hold in the U.S. after the FDA issued a warning letter related to the El Paso facility. He added that the testing process tied to the issue was expected to take about three weeks and said no patient safety signals had been identified.
Becton, Dickinson and Company (NYSE:BDX) develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products used by healthcare institutions, physicians, researchers, and clinical laboratories worldwide.
While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Micro-Cap Dividend Stocks To Buy Now and 10 Best Stocks to Buy Now for a $1 Million Portfolio
Disclosure: None. Follow Insider Monkey on Google News.
